The durability of abatacept as a first and subsequent biologic and improvement in HAQ from a large multi-site real-world study

Seminars in Arthritis and Rheumatism

Volumn 44, Issue 5, 2015, Pages 499-505

  Pope, Janet E ^a   Rampakakis, Emmanouil ^b   Sampalis, John ^b,c  

^a UNIVERSITY OF WESTERN ONTARIO   (Canada)

^b JSS Medical Research   (Canada)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

Abatacept; Cohort; Comorbidities; Database; Durability; First biologic; Function; HAQ; Health Joseph's health caredisability index; Number needed to treat (NNT); Post TNFi; Real world practice; Rheumatoid arthritis (RA)

Indexed keywords

ABATACEPT; CHOLESTEROL; METHOTREXATE; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT;

ADULT; ANEMIA; ARTICLE; ASTHMA; CANADA; CANADIAN; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; CLINICAL STUDY; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; DIABETES MELLITUS; DISEASE DURATION; DRUG EFFICACY; DRUG WITHDRAWAL; FELTY SYNDROME; FEMALE; GASTROESOPHAGEAL REFLUX; HEALTH ASSESSMENT QUESTIONNAIRE; HEART INFARCTION; HEMOGLOBINOPATHY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; INTERSTITIAL LUNG DISEASE; IRITIS; LUNG FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIGRAINE; NUMBERS NEEDED TO TREAT; OSTEOARTHRITIS; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; PLEURISY; PRIORITY JOURNAL; PSORIASIS; RAYNAUD PHENOMENON; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SURVIVAL RATE; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT DURATION; UVEITIS; VASCULITIS; AGED; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; DISABILITY; HEALTH STATUS; MIDDLE AGED; MULTICENTER STUDY; REMISSION; TREATMENT OUTCOME;

ABATACEPT; ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; DISABILITY EVALUATION; FEMALE; HEALTH STATUS; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84926366739     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2014.09.009     Document Type: Article

References (30)

1. Benson K., Hartz A.J. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000, 342:1878-1886.
2. Karsh J., Keystone E.C., Haraoui B., Thorne J.C., Pope J.E., Bykerk V.P., et al. Canadian recommendations for clinical trials of pharmacologic interventions in rheumatoid arthritis: inclusion criteria and study design. J Rheumatol 2011, 38:2095-2104. [Epub 2011 Jul 15, PMID: 21765109].
3. Pease C., Pope J., Truong D., Bombardier C., Widdifield J., Thorne C., et al. Comparison of anti-TNF treatment initiation in RA databases demonstrates wide country variability in patient parameters at initiation of anti-TNF therapy. Semin Arthritis Rheum 2011, 41(1):81-89. doi:10.1016/j.semarthrit.2010.09.004 [Epub 2010 Dec 17].
4. Kremer J.M., Dougados M., Emery P., Durez P., Sibilia J., Shergy W., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:2263-2271.
5. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006, 144:865-876.
6. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2008, 67:1096-1103. [Epub 2007 Nov 29].
7. Genovese M.C., Becker J.C., Schiff M., Luggen M., Sherrer Y., Kremer J., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005, 353:1114-1123.
8. Kremer J.M., Westhovens R., Leon M., Di Giorgio E., Alten R., Steinfeld S., et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907-1915.
9. Du Pan S.M., Scherer A., Gabay C., Finckh A. Differential drug retention between anti-TNF agents and alternative biological agents after inadequate response to an anti-TNF agent in rheumatoid arthritis patients. Ann Rheum Dis 2012, 71:997-999. [Epub 2012 Jan 30]. 10.1136/annrheumdis-2011-200882.
10. Gomez-Reino J.J., Maneiro J.R., Ruiz J., Roselló R., Sanmarti R., Romero A.B., et al. Comparative effectiveness of switching to alternative tumour necrosis factor (TNF) antagonists versus switching to rituximab in patients with rheumatoid arthritis who failed previous TNF antagonists: the MIRAR Study. Ann Rheum Dis 2012, 71:1861-1864. [Epub 2012 Jun 26]. 10.1136/annrheumdis-2012-201324.
11. Gómez-Reino J.J., Rodríguez-Lozano C., Campos-Fernández C., Montoro M., Descalzo M.Á., Carmona L. Change in the discontinuation pattern of tumour necrosis factor antagonists in rheumatoid arthritis over 10 years: data from the Spanish registry BIOBADASER 2.0. Ann Rheum Dis 2012, 71:382-385. [Epub 2011 Oct 13]. 10.1136/annrheumdis-2011-200302.
12. Rémy A., Avouac J., Gossec L., Combe B. Clinical relevance of switching to a second tumour necrosis factor-alpha inhibitor after discontinuation of a first tumour necrosis factor-alpha inhibitor in rheumatoid arthritis: a systematic literature review and meta-analysis. Clin Exp Rheumatol 2011, 29:96-103. [Epub 2011 Feb 23].
13. Fries J.F., Spitz P., Kraines R.G., Holman H.R. Measurement of patient outcome in arthritis. Arthritis Rheum 1980, 23:137-145.
14. Yelin E., Trupin L., Wong B., Rush S. The impact of functional status and change in functional status on mortality over 18 years among persons with rheumatoid arthritis. J Rheumatol 2002, 29:1851-1857.
15. Farragher T.M., Lunt M., Bunn D.K., Silman A.J., Symmons D.P. Early functional disability predicts both all-cause and cardiovascular mortality in people with inflammatory polyarthritis: results from the Norfolk Arthritis Register. Ann Rheum Dis 2007, 66:486-492.
16. Wolfe F., Michaud K., Gefellar O., Choi H.K. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003, 48:1530-1542.
17. Bansback N.J., Brennan A., Ghatnekar O. Cost effectiveness of adalimumab in the treatment of patients with moderate to severe rheumatoid arthritis in Sweden. Ann Rheum Dis 2005, 64:995-1002.
18. Antoni C., Krueger G.G., de Vlam K., Birbara C., Beutler A., Guzzo C., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157.
19. Wolfe F., Michaud K. Towards an epidemiology of rheumatoid arthritis outcome with respect to treatment: randomized controlled trials overestimate treatment response and effectiveness. Rheumatology 2005, 44:iv18-iv22.
20. Hyrich K.L., Watson K.D., Silman A.J., Symmons D.P.M. Predictors of response to anti-TNF therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 2006, 45:1558-1565.
21. Wolfe F., Michaud K., Strand V. Expanding the definition of clinical differences: from minimally clinically important differences to really important differences. Analyses in 8931 patients with rheumatoid arthritis. J Rheumatol 2005, 32:583-589.
22. Barra L., Pope J., Payne M. The cost-effectiveness of anti-TNF agents in rheumatic disorders as measured by the minimally clinical important difference (MCID) in the Health Assessment Questionnaire (HAQ). J Rheumatol 2009, 36:1421-1428.
23. Yazici Y., Moniz Reed D., Klem C., Rosenblatt L., Wu G., Kremer J.M. Greater remission rates in patients with early versus long-standing disease in biologic-naive rheumatoid arthritis patients treated with abatacept: a post hoc analysis of randomized clinical trial data. Clin Exp Rheumatol 2011, 29:494-499. [Epub 2011 Jun 29].
24. Schiff M., Keiserman M., Codding C., Songcharoen S., Berman A., Nayiager S., et al. Clinical response and tolerability to abatacept in patients with rheumatoid arthritis previously treated with infliximab or abatacept: open-label extension of the ATTEST Study. Ann Rheum Dis 2011, 70:2003-2007. [Epub 2011 Sep 12]. 10.1136/annrheumdis-2011-200316.
25. Kremer J.M., Russell A.S., Emery P., Abud-Mendoza C., Szechinski J., Westhovens R., et al. Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial. Ann Rheum Dis 2011, 70:1826-1830. 10.1136/ard.2010.139345.
26. Kremer J.M., Genant H.K., Moreland L.W., Russell A.S., Emery P., Abud-Mendoza C., et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. Arthritis Rheum 2008, 58:953-963. 10.1002/art.23397.
27. Genovese M.C., Schiff M., Luggen M., Becker J.C., Aranda R., Teng J., et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. Ann Rheum Dis. 2008, 67:547-554. [Epub 2007 Oct 5].
28. Iannone F, Atzeni F, Biasi D, Botsios C, Cipriani P, Ferraccioli G, et al. Long-term survival of anti-TNF therapy in a large Italian cohort of rheumatoid arthritis patients: comparison among adalimumab, etanercept and infliximab. Presented at EULAR, THU0232, 2011.
29. Guyot P., Taylor P.C., Christensen R., Pericleous L., Drost P., Eijgelshoven I., et al. Indirect treatment comparison of abatacept with methotrexate versus other biologic agents for active rheumatoid arthritis despite methotrexate therapy in the United kingdom. J Rheumatol 2012, 39:1198-1206. [Epub 2012 Apr 15]. 10.3899/jrheum.111345.
30. Weinblatt M.E., Schiff M., Valente R., van der Heijde D., Citera G., Zhao C., et al. Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: Findings of a phase IIIb, multinational, prospective, randomized study. Arthritis Rheum 2013, 65:28-38. 10.1002/art.37711.